Blurbs

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Vincerx Pharma Inc (VINC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novo Nordisk (NVOResearch Report) and Vincerx Pharma Inc (VINCResearch Report) with bullish sentiments.

Novo Nordisk (NVO)

In a report released today, Richard Vosser from J.P. Morgan upgraded Novo Nordisk to Buy. The company’s shares closed last Monday at $112.15.

According to TipRanks.com, Vosser is a 5-star analyst with an average return of 12.1% and a 67.2% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Molecular Partners, and Roche Holding AG.

Novo Nordisk has an analyst consensus of Strong Buy, with a price target consensus of $130.00, implying a 15.4% upside from current levels. In a report issued on May 31, Guggenheim also upgraded the stock to Buy.

See Insiders’ Hot Stocks on TipRanks >>

Vincerx Pharma Inc (VINC)

In a report released today, Jonathan Chang from SVB Securities maintained a Buy rating on Vincerx Pharma Inc, with a price target of $6.00. The company’s shares closed last Monday at $1.83, close to its 52-week low of $1.40.

According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of -20.3% and a 22.7% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vincerx Pharma Inc with a $16.00 average price target, which is a 784.0% upside from current levels. In a report released today, B.Riley Financial also maintained a Buy rating on the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos